2026 Peptide Regulatory Tracker: FDA, 503A & PCAC Status

Last updated: 2026-06-09. Next scheduled review: after the July 23–24, 2026 PCAC outcome (and on any earlier FDA or Federal Register action). This page is the dated status of record that the rest of Peptevity links back to.

Direct answer

As of 2026-06-09, the U.S. peptide regulatory picture turns on three events. First, on April 15, 2026 the FDA announced it was removing 12 peptides (including BPC-157, TB-500, MOTS-c, KPV, DSIP, Epitalon, Semax, GHK-Cu injectable, and Melanotan II) from its interim 503A Category 2 "do-not-compound" list, effective on or about April 22, 2026, because the nominations were withdrawn — removal is not approval and not authorization to compound (Federal Register, docket FDA-2025-N-6895). Second, a PCAC meeting on July 23–24, 2026 will vote on moving seven of those peptides toward the 503A bulks list (FDA advisory-committee calendar). Third, a second PCAC review before the end of February 2027 covers the remaining group, including GHK-Cu and Melanotan II. None of these peptides is an FDA-approved drug; most are sold "research use only — not for human consumption."

This page is research and educational information, not medical advice. Peptevity sells nothing, recommends no product or vendor, and publishes no human-dosing or self-administration instructions. The compounds tracked below are, in nearly every case, not FDA-approved and are marketed under a "research use only" label; "research use only" is a legal category for laboratory reagents, not a clearance for human use — see what "research use only" means and whether peptides are legal. Where this page touches efficacy or safety, claims are graded per our evidence-grading methodology; the regulatory facts are sourced to FDA and the Federal Register.

The status table (status of record, as of 2026-06-09)

This is the primary table the rest of the site references. "503A category history" reflects each substance's path through the FDA's interim 503A categories; "PCAC group & date" shows which advisory-committee review (if any) the substance is assigned to. "Last-checked" is the date Peptevity last verified the row against primary sources.

Sources for the table: Federal Register, docket FDA-2025-N-6895; FDA — July 23–24, 2026 PCAC calendar; FDA — bulk drug substances under 503A; FDA — Concerns with Unapproved GLP-1 Drugs.

How to read the 503A framework

The acronym at the center of this whole story is 503A — Section 503A of the Federal Food, Drug, and Cosmetic Act, which lets a pharmacy compound a drug for an individual patient from a bulk drug substance under defined conditions. A bulk substance qualifies if it has a USP/NF monograph, is a component of an FDA-approved drug, or appears on the 503A bulks list the FDA maintains (FDA — 503A bulk drug substances). For substances nominated to that list but not yet decided, the FDA has used interim categories:

• Category 1 — "may compound" pending review. Substances the FDA does not currently intend to act against while evaluation continues — i.e., enforcement discretion. This is interim, not the same as being formally placed on the 503A bulks list.
• Category 2 — "do not compound." Substances that raise significant safety concerns. The FDA's interim position is that it may take enforcement action against compounding these. Most of the peptides on this tracker sat here before April 2026.
• Category 3 — pending further evaluation. Substances nominated without enough supporting information to evaluate; effectively parked awaiting data.

The single most-misread fact of 2026 is what the April removal did. Taking a peptide out of Category 2 does not put it on the bulks list and does not move it to Category 1; in the FDA's framing, "removal from Category 2 does not render these bulk drug substances eligible for compounding under section 503A." The substances are simply un-categorized while the agency runs them through advisory-committee review. Removal is not approval, and it is not a green light to compound. We labor this point because vendor and influencer content collapsed "removed from the do-not-compound list" into "now legal" almost overnight, which is not what happened.

What happened in April 2026

On April 15, 2026, the FDA announced it was removing 12 peptide bulk drug substances from the interim 503A Category 2 list, with the removal effective within seven days (on or about April 22, 2026). The stated reason was procedural: the original nominations were withdrawn by the nominators, so the agency had no live nomination to keep evaluating in Category 2 (Federal Register, docket FDA-2025-N-6895).

The 12 substances were BPC-157, Cathelicidin LL-37, Dihexa, DSIP (emideltide), Epitalon, GHK-Cu (injectable routes), KPV, PEG-MGF (pegylated mechano growth factor), Melanotan II, MOTS-c, Semax, and TB-500 (thymosin β-4 fragment). For GHK-Cu specifically, the non-injectable route was removed from Category 1 and the injectable route from Category 2 — both because the nominations were withdrawn, not because either was found safe to compound (FDA — 503A bulk drug substances).

The Federal Register notice that accompanied this — docket FDA-2025-N-6895, published 2026-04-16 — did two things at once: it documented the Category 2 removals and announced the advisory-committee process that would decide what comes next (Federal Register, docket FDA-2025-N-6895). That is the bridge to the two PCAC reviews below.

The July 23–24, 2026 PCAC review (group one)

The Pharmacy Compounding Advisory Committee (PCAC) is the FDA's expert panel for compounding questions. Its July 23–24, 2026 meeting at the FDA's White Oak campus will consider whether seven peptides should be added to the 503A bulk drug substances list — the formal step that, if the agency later agrees, would let pharmacies compound them for individual patients (FDA — July 23–24, 2026 PCAC calendar).

The seven, and how the two days are split, are:

• Day 1 (July 23, 2026): BPC-157, KPV, TB-500, and MOTS-c.
• Day 2 (July 24, 2026): DSIP (emideltide), Semax, and Epitalon.

Three things are worth keeping straight. First, a PCAC vote is a recommendation; the FDA makes the final listing decision afterward, so a "yes" on July 24 is not the same as a substance being on the bulks list — formal addition to the 503A bulks list still requires FDA rulemaking that follows, and lands substantially later than, the committee vote. Second, even a successful listing would authorize compounding under prescription, not over-the-counter sale or self-administration — and it would not make any of these an FDA-approved drug. Third, the public docket (FDA-2025-N-6895) was open for written comment ahead of the meeting (the comment window ran through July 22, 2026 via regulations.gov); we treat the comment window and agenda as the FDA states them and will re-date this section against the agency's primary postings (Federal Register, docket FDA-2025-N-6895).

The second PCAC review (group two — before end of February 2027)

The remaining substances from the April group are not in the July hearing. They are assigned to a second PCAC consultation expected before the end of February 2027, and that group includes GHK-Cu and Melanotan II (Federal Register, docket FDA-2025-N-6895). This is why the copper peptide GHK-Cu monograph carries a February-2027 date rather than a July-2026 one — a distinction that is easy to get wrong, because the same April notice covers both groups. If you see GHK-Cu described as part of the July hearing, that is an error; the topical cosmetic lane for GHK-Cu is unaffected by either review and remains a permitted cosmetic-ingredient use (FDA — 503A bulk drug substances).

We will date and update this section against the FDA's primary postings once the second meeting is formally noticed; as of 2026-06-09 the "before end of February 2027" window is the agency's stated plan, not a confirmed calendar date.

Why retatrutide is on a different track entirely

Retatrutide appears in the table because it is the highest-profile investigational peptide of 2026, but its regulatory situation has nothing to do with the 503A peptide reviews. Retatrutide is Eli Lilly's GIP/GLP-1/glucagon triple agonist (code LY3437943), still in Phase 3; the pivotal TRIUMPH-1 trial reported topline results on 2026-05-21 (mean ~28.3% weight loss at 80 weeks on the 12 mg dose) (Lilly investor release, May 2026). It is not approved anywhere and its path to market is the standard new-drug application, not an advisory-committee bulks-list vote.

It also cannot be legally compounded. Unlike semaglutide and tirzepatide — which were briefly compoundable while on the drug-shortage list — retatrutide has never had an approved version, so no shortage exemption ever applied. The FDA states compounded retatrutide is not eligible for the 503A or 503B exemptions, and in September 2025 issued warning letters describing sold "research" retatrutide as unapproved new drugs and misbranded drugs (FDA — Concerns with Unapproved GLP-1 Drugs). For the difference between an investigational drug and an approved one, see investigational versus approved.

The approved comparators — what "approved" actually looks like

To keep the grades honest, the table includes three peptides that are FDA-approved, so the contrast is visible:

• Semaglutide — a GLP-1 mono-agonist, FDA-approved and marketed as Ozempic, Wegovy, and Rybelsus.
• Tirzepatide — a GIP/GLP-1 dual agonist, FDA-approved and marketed as Mounjaro and Zepbound.
• Tesamorelin — a GHRH analog, FDA-approved (Egrifta SV / Egrifta WR) for HIV-associated lipodystrophy.

These three went through full new-drug review, carry FDA-approved labeling, and are made under Good Manufacturing Practice. That is what a finished approval looks like — and it is precisely what none of the 503A-review peptides, and not retatrutide, have as of 2026-06-09. We cover semaglutide, tirzepatide, and the branded GLP-1 drugs only as comparators; they are FDA-approved branded medicines outside Peptevity's research-peptide editorial lane.

How this page is maintained

This tracker is a living, dated document, and the date at the top is load-bearing. Our maintenance rule is simple: re-verify every row against FDA and Federal Register primary sources on each scheduled review, and re-date the page whenever a primary source changes. The next scheduled review is after the July 23–24, 2026 PCAC outcome, with earlier updates triggered by any intervening FDA action (a new Federal Register notice, a warning letter, an approval, or a bulks-list change). When a status changes, the row's "last-checked" date moves and the change is logged under our corrections policy. For how we choose and cite sources, see our sourcing and citation policy and editorial standards.

Honest bottom line

The headline of 2026 is easy to misread, so here it is plainly: the FDA removed 12 peptides from a "do-not-compound" list because the paperwork behind them was withdrawn, and then scheduled expert reviews to decide what should happen next. Removal is not approval. A PCAC vote is not approval. Being on the 503A bulks list is not drug approval — it is permission to compound under prescription, which is a narrower thing than the marketing implies. Seven peptides (BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon, Semax) go before the committee on July 23–24, 2026; a second group, including GHK-Cu and Melanotan II, follows before the end of February 2027. Retatrutide is investigational and on a separate, stricter track. Everything here is dated 2026-06-09 for a reason — this lane moves, and a tracker is only as good as its last verification.

Frequently asked questions

Did the FDA legalize BPC-157 and the other peptides in April 2026? No. On April 15, 2026 the FDA announced it was removing 12 peptides — including BPC-157, TB-500, MOTS-c, KPV, DSIP, Epitalon, Semax, GHK-Cu (injectable), and Melanotan II — from its interim 503A Category 2 "do-not-compound" list, effective on or about April 22, 2026, because the nominations were withdrawn. In the FDA's own framing, removal from Category 2 does not place these substances on the 503A bulks list, does not move them to Category 1, and does not make them eligible for compounding (Federal Register, docket FDA-2025-N-6895; FDA — 503A bulk drug substances). Removal is not approval.

Which peptides are reviewed at the July 23–24, 2026 PCAC meeting? Seven: BPC-157, KPV, TB-500, and MOTS-c on Day 1, and DSIP (emideltide), Semax, and Epitalon on Day 2. The Pharmacy Compounding Advisory Committee meets at the FDA's White Oak campus to consider whether each should be added to the 503A bulk drug substances list (FDA — July 23–24, 2026 PCAC calendar). A committee vote is a recommendation; the FDA makes the final listing decision.

Is GHK-Cu part of the July 2026 hearing? No. GHK-Cu (and Melanotan II) are assigned to a separate, second PCAC review expected before the end of February 2027, not the July 23–24, 2026 meeting (Federal Register, docket FDA-2025-N-6895). The topical cosmetic use of the copper tripeptide is unaffected by either review; see the GHK-Cu monograph for the lane-by-lane detail.

What is the difference between 503A Category 1 and Category 2? Category 1 is the interim "may compound" group, where the FDA exercises enforcement discretion while evaluation continues; Category 2 is the "do-not-compound" group of substances that raise significant safety concerns. Neither is the same as formal placement on the 503A bulks list, which is the step the July 2026 PCAC review is working toward (FDA — 503A bulk drug substances).

Is retatrutide affected by the 503A peptide reviews? No. Retatrutide is an investigational Eli Lilly triple agonist on the standard new-drug pathway, not the 503A compounding track. It has never been on a bulks list, is not eligible for 503A or 503B compounding, and is not FDA-approved anywhere as of June 2026; the FDA has issued warning letters about gray-market "research" retatrutide (FDA — Concerns with Unapproved GLP-1 Drugs). See retatrutide and investigational versus approved.

When will this tracker be updated next? The next scheduled review is after the July 23–24, 2026 PCAC outcome, with earlier updates triggered by any intervening FDA or Federal Register action. Each scheduled review re-verifies every row against primary sources and re-dates the page; changes are logged under our corrections policy.

How we graded this page

This is a dated regulatory tracker, not an efficacy or safety claim. Every regulatory statement is tied to an FDA or Federal Register primary source per our evidence-grading methodology and sourcing and citation policy. Peptevity carries no advertising, no affiliate links, and sells nothing — see our conflict-of-interest and funding statement, and our medical disclaimer and RUO statement.

Primary sources

• Federal Register / U.S. FDA. Pharmacy Compounding Advisory Committee — Notice of Meeting; Establishment of a Public Docket; Request for Comments (July 23–24, 2026); docket FDA-2025-N-6895 (published 2026-04-16; FR doc. 2026-07361). https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
• U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
• U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
• U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
• Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline; 2026-05-21). https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html

External references appear as citations only; none of the cited institutions endorse, review, or are affiliated with Peptevity.

Related on Peptevity

• The BPC-157 monograph — a July-2026 PCAC peptide, graded.
• The TB-500 monograph — the other July Day-1 tissue-repair peptide.
• The GHK-Cu monograph — the copper peptide in the February-2027 group.
• The retatrutide monograph — the investigational triple agonist on a separate track.
• Are peptides legal? — the compounding and gray-market lanes explained.
• What "research use only" means — the RUO label as a legal category.
• Investigational versus approved — why retatrutide is not semaglutide.
• How Peptevity grades evidence — the A–F evidence scale.